Recombinant von Willebrand Factor: Preclinical Development

ABSTRACT

Von Willebrand factor (vWF) is a multimeric glycoprotein (GP) that attracts platelets to the site of vascular injury, mediates platelet-platelet interaction, and stabilizes factor VIII (FVIII) in the circulation. Quantitative and qualitative defects of vWF result in von Willebrand disease (vWD), manifested by modest to severe bleeding episodes. Substitution therapy, with plasma-derived FVIII/vWF complex concentrates, is used for patients suffering the more severe forms of vWD. Efficacy of these preparations is often unsatisfactory because inadvertent proteolytic degradation during the manufacturing process causes them to lack the hemostatically most active high-molecular-weight multimers. In contrast, recombinant vWF (r-vWF), which is constitutively expressed at high yields in Chinese hamster ovary (CHO) cells and secreted into the conditioned medium under perfusion fermentation in ``protein-free'' medium, has high-molecular-weight multimers of extraordinary structural integrity. Functional analysis has shown that r-vWF promotes ristocetin cofactor-mediated platelet aggregation, collagen interaction and FVIII binding, and platelet-collagen adhesion under shear stress. Infusing vWF-deficient animals with r-vWF corrected vWF concentration and reduced blood loss, subsequently stabilizing endogenous FVIII associated with the reduction of bleeding time. Compared with plasma-derived vWF preparations, r-vWF was found to have a prolonged half-life, further enhancing the potential value of r-vWF as a therapeutic agent for treating patients suffering from vWD.

KEYWORD

von Willebrand factor - recombinant expression - multimers - biological activity - animal model

REFERENCES

• 1 Sadler J E. Biochemistry and genetics of von Willebrand factor.  Annu Rev Biochem . 1998;  67 395-424
• 2 Ruggeri Z M. Structure and function of von Willebrand factor.  Thromb Haemost . 1999;  82 576-584
• 3 Federici A B. Diagnosis of von Willebrand disease.  Haemophilia . 1998;  4 654-660
• 4 Ginsburg D. The molecular biology of von Willebrand disease.  Haemophilia . 1999;  5 19-27
• 5 Sadler J E. A revised classification of von Willebrand disease.  Thromb Haemost . 1994;  71 520-525
• 6 Sadler J E, Mannucci P M, Berntorp E. Impact, diagnosis and treatment of von Willebrand disease.  Thromb Haemost . 2000;  84 160-174
• 7 Mannucci P M. Treatment of von Willebrand disease.  Haemophilia . 1998;  4 661-664
• 8 Mannucci P M. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first twenty years.  Haemophilia . 2000;  6 60-67
• 9 Berntorp E. Plasma product treatment in various types of von Willebrand's disease.  Haemostasis . 1994;  24 289-297
• 10 Dobrkovska A, Krzensk U, Chediak J R. Pharmacokinetics, efficacy and safety of Humate-P in von Willebrand disease.  Haemophilia . 1998;  4 33-39
• 11 Berntorp E. Von Willebrand factor containing factor VIII concentrates.  Haemophilia . 1999;  5 60-63
• 12 Mannucci P M, Tenconi P M, Castaman G. Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: a cross-over randomized trial.  Blood . 1992;  79 3130-3137
• 13 Mannucci P M. Biochemical characteristics of therapeutic plasma concentrates used in the treatment of von Willebrand disease.  Haemostasis . 1994;  24 285-288
• 14 Meyer D, Girma J-P. Von Willebrand factor: structure and function.  Thromb Haemost . 1993;  70 99-104
• 15 Furlan M. Von Willebrand factor: molecular size and functional activity.  Ann Hematol . 1996;  72 341-348
• 16 Wise R J, Barr P J, Wong P A. Expression of a human proprotein processing enzyme: Correct cleavage of the von Willebrand factor precursor at a paired basic amino acid site.  Proc Natl Acad Sci USA . 1990;  87 9378-9382
• 17 Himmelspach M, Plaimauer B, Dorner F. Furin as a tool for the endoproteolytic maturation of susceptible recombinant biopharmaceuticals. In: von Broekhoven A, Shapiro F, Anné J, eds. Novel Frontiers in the Production of Compounds for Biomedical Use Dordrecht, The Netherlands: Kluwer; 2001: 219-248
• 18 Birch K A, Pober J S, Zavoico G B. Calcium/calmodulin transduces thrombin-stimulated secretion: studies in intact and minimally permeabilized human umbilical vein endothelial cells.  J Cell Biol . 1992;  118 1501-1510
• 19 Ribes J A, Francis C W, Wagner D D. Fibrin induces release of von Willebrand factor from endothelial cells.  J Clin Invest . 1987;  79 117-123
• 20 Sporn L A, Marder V J, Wagner D D. Inducible secretion of large, biologically potent von Willebrand factor multimers.  Cell . 1986;  46 185-190
• 21 Ewenstein B M, Warhol M J, Handin R I. Composition of the von Willebrand factor storage organelle (Weibel-Palade body) isolated from cultured human umbilical vein endothelial cells.  J Cell Biol . 1987;  104 1423-1433
• 22 Sporn L A, Marder V J, Wagner D D. Von Willebrand factor released from Weibel-Palade bodies binds more avidly to extracellular matrix than that secreted constitutively.  Blood . 1987;  69 1531-1534
• 23 Tsai H M, Nagel R L, Hatcher V B. Multimeric composition of endothelial cell-derived von Willebrand factor.  Blood . 1989;  73 2074-2076
• 24 Dent J A, Berkowitz S D, Ware J. Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor.  Proc Natl Acad Sci USA . 1990;  87 6306-6310
• 25 Dent J A, Galbusera M, Ruggeri Z M. Heterogeneity of plasma von Willebrand factor multimers resulting from proteolysis of the constituent subunit.  J Clin Invest . 1991;  88 774-782
• 26 Furlan M, Robles R, Affolter D. Triplet structure of von Willebrand factor reflects proteolytic degradation of high molecular weight multimers.  Proc Natl Acad Sci USA . 1993;  90 7503-7507
• 27 Fischer B E, Thomas K B, Schlokat U. Triplet structure of human von Willebrand factor.  Biochem J . 1998;  331 483-488
• 28 Furlan M, Robles R, Lamie B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis.  Blood . 1996;  87 4223-4234
• 29 Sadler J E, Shelton-Inloes B B, Sorace J M. Cloning of cDNA and genomic DNA for human von Willebrand factor.  Cold Spring Harb Symp Quant Biol . 1986;  51 515-523
• 30 Bonthron D T, Handin R I, Kaufman R J. Structure of pre-pro-von Willebrand factor and its expression in heterologous cells.  Nature . 1986;  324 270-273
• 31 Meulien P, Nishino M, Mazurier C. Processing and characterization of recombinant von Willebrand factor expressed in different cell types using a vaccinia virus vector.  Thromb Haemost . 1992;  67 154-160
• 32 Fischer B, Mitterer A, Schlokat U. Structural analysis of recombinant von Willebrand factor: identification of hetero- and homo-dimers.  FEBS Lett . 1994;  351 345-348
• 33 Schlokat U, Fischer B, Mitterer A. Herstellung und Charakterisierung von rekombinantem von Willebrand- Faktor zur therapeutischen Anwendung. In: Scharrer I, Schramm W, eds. 26 Hämophilie-Symposium Hamburg 1995 Berlin, Germany: Springer Verlag Publishers 1996: 147-158
• 34 Fischer B E, Schlokat U, Mitterer A. Structural analysis of recombinant von Willebrand factor produced at industrial scale fermentation of transformed CHO cells co-expressing recombinant furin.  FEBS Lett . 1995;  375 259-262
• 35 Fischer B E, Schlokat U, Reiter M. Biochemical and functional characterization of recombinant von Willebrand factor produced on a large scale.  Cell Mol Life Sci . 1997;  53 943-950
• 36 Rehemtulla A, Dorner A J, Kaufman R J. Regulation of PACE4 propeptide-processing activity: Requirement for a post-endoplasmic reticulum compartment and autoproteolytic activation.  Proc Natl Acad Sci USA . 1992;  89 8235-8239
• 37 Rehemtulla A, Kaufman R J. Preferred sequence requirements for cleavage of pro-von Willebrand factor by propeptide-processing enzymes.  Blood . 1992;  79 2349-2355
• 38 Schlokat U, Fischer B E, Herlitschka S. Production of highly homogeneous and structurally intact recombinant von Willebrand factor multimers by furin-mediated propeptide removal in vitro.  Biotechnol Appl Biochem . 1996;  24 257-267
• 39 Hatsuzawa K, Nagahama M, Takahashi S. Purification and characterization of Furin, a Kex2-like processing endoprotease, produced in Chinese hamster ovary cells.  J Biol Chem . 1992;  267 16094-16099
• 40 Vidricaire G, Denault J-B, Leduc R. Characterization of a secreted form of human furin endoprotease.  Biochem Biophys Res Commun . 1993;  195 1011-1018
• 41 Vey M, Schäfer W, Berghöfer S. Maturation of trans-Golgi network protease Furin: Compartmentalization of propeptide removal, substrate cleavage, and COOH-terminal truncation.  J Cell Biol . 1994;  127 1829-1842
• 42 Preininger A, Schlokat U, Mohr G. Strategies for recombinant furin employment in a biotechnological process: complete target protein precursor cleavage.  Cytotechnol . 1999;  30 1-15
• 43 Fischer B, Mitterer A, Dorner F. Comparison of N-glycan pattern of recombinant human coagulation factors II and IX expressed in Chinese hamster ovary (CHO) and African green monkey (Vero) cells.  J Thromb Thrombolysis . 1996;  3 57-62
• 44 Plaimauer B, Schlokat U, Himmelspach M. Posttranslational modifications of recombinant von Willebrand factor: limitations and experimental improvement at high yield expression. In: Ikura K, Nagao M, Masuda S, Sasaki R, eds. Animal Cell Technology: Challenges for the 21st Century Dordrecht, The Netherlands: Kluwer 1999: 105-109
• 45 Schwarz H P, Turecek P L, Pichler L. Recombinant von Willebrand factor.  Thromb Haemost . 1997;  78 571-576
• 46 Siekmann J, Turecek P L, Schwarz H P. The determination of von Willebrand factor activity by collagen binding assay.  Haemophilia . 1998;  4 15-24
• 47 Fischer B E, Kramer G, Mitterer A. Effect of multimerization of human and recombinant von Willebrand factor on platelet aggregation, binding to collagen and binding of coagulation factor VIII.  Thromb Res . 1996;  84 55-66
• 48 Malmqvist M. BIACORE: an affinity biosensor system for characterization of biomolecular interactions.  Biochem Soc Trans . 1999;  27 335-340
• 49 Vlot A J, Koppelman S J, van den Berg H M. The affinity and stoichiometry of binding of human factor VIII to von Willebrand factor.  Blood . 1995;  85 3150-3157
• 50 Leyte A, Verbeet M P, Brodniewicz-Proba T. The interaction between human blood-coagulation factor VIII and von Willebrand factor. Characterization of a high-affinity binding site on factor VIII.  Biochem J . 1989;  257 679-683
• 51 Wise R J, Dorner A J, Krane M. The role of von Willebrand factor multimers and propeptide cleavage in binding and stabilization of Factor VIII.  J Biol Chem . 1991;  266 21948-21955
• 52 Bendetowicz A V, Morris J A, Wise R J. Binding of factor VIII to von Willebrand factor is enabled by cleavage of the von Willebrand factor propeptide and enhanced by formation of disulfide-linked multimers.  Blood . 1998;  92 529-538
• 53 Turecek P, Siekman J, Pichler L. Rekombinanter von Willebrand-Faktor: Präklinik. In: Scharrer I, Schramm W, eds. 26 Hämophilie-Symposium Hamburg 1995 Berlin, Germany: Springer Verlag Publishers 1996: 159-168
• 54 Turecek P L, Gritsch H, Richter G. Assessment of bleeding for the evaluation of therapeutic preparations in small animal models of antibody-induced hemophilia and von Willebrand disease.  Thromb Haemost . 1997;  77 591-599
• 55 Turecek P L, Gritsch H, Pichler L. In vivo characterization of recombinant von Willebrand factor in dogs with von Willebrand disease.  Blood . 1997;  90 3555-3567
• 56 Turecek P L, Pichler L, Auer W. Evidence for extracellular processing of pro-von Willebrand factor after infusion in animals with and without severe von Willebrand disease.  Blood . 1999;  94 1637-1647
• 57 Roussi J, Turecek P L, Andre P. Effects of human recombinant, plasma-derived and porcine von Willebrand factor in pigs with severe von Willebrand disease.  Blood Coagul Fibrinolysis . 1998;  9 361-372
• 58 Borchiellini A, Fijnvandraat K, ten Cate W J. Quantitative analysis of von Willebrand factor propeptide release in vivo: effect of experimental endotoxemia and administration of 1-deamino-8-D-arginine vasopressin in humans.  Blood . 1996;  88 2951-2958